← Leaderboards
Mario Stevenson
Univ Of Massachusetts Med Sch Worcester
$40,259,093
Attributed
$42,587,396
Total exposure
30
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$64,610,769 · 33
By mechanism
R01$21,553,787 · 9
P01$13,455,346 · 5
P30$11,592,734 · 2
U19$10,629,434 · 4
R37$3,558,909 · 1
R21$1,376,681 · 3
Top collaborators
- Emmanuel Thomas6 shared
- Adam Wayne Carrico3 shared
- Hansel Emory Tookes3 shared
Others in their field
Top investigators on “Macrophage”
- Craig B Thompson · Sloan-Kettering Inst Can Research$41,669,179
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$41,668,744
- Selwyn M Vickers · University Of Alabama At Birmingham$40,969,055
- Alan A Aderem · University Of Washington$38,969,733
- Alan Richard Tall · Columbia University Health Sciences$38,053,695
- John S Condeelis · Yeshiva University$33,855,255
Research focus
MacrophageHiv-1ViralVirusCellsInfectionResearch PersonnelInsightIn VivoDesignCd4 Positive T LymphocytesPlasmaExhibitsMolecularVariantInhibitor/AntagonistPhenotypeProgramsMediatingMacacaTissuesPlayBaseIn Vitro
Grant awards (158)
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection$632,239
R01 · FY2025 · DA · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$524,967
R01 · FY2025 · MH · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART$496,980
R01 · FY2025 · DK · contact PI
Developmental Research Program$70,457
U54 · FY2025 · CA · contact PI
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection$640,539
R01 · FY2024 · DA · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$524,967
R01 · FY2024 · MH · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART$477,100
R01 · FY2024 · DK · contact PI
Irreversible Proviral Silencing in Myeloid Cells$230,250
R21 · FY2024 · AI · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART$60,177
R01 · FY2024 · DK · contact PI
Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection$663,951
R01 · FY2023 · DA · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$538,346
R01 · FY2023 · MH · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART$510,355
R01 · FY2023 · DK · contact PI
Irreversible Proviral Silencing in Myeloid Cells$191,875
R21 · FY2023 · AI · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART-SUPPLEMENT 1$60,177
R01 · FY2023 · DK · contact PI
Defining a Role for Liver Myeloid Cells in Viral Persistence under ART$469,512
R01 · FY2022 · DK · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$383,750
R01 · FY2022 · MH · contact PI
Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings$299,999
R41 · FY2022 · AI · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$383,750
R01 · FY2021 · MH · contact PI
Reservoir activity and recrudescent virus composition in HIV and SIV rebound$295,865
P01 · FY2021 · AI · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$383,750
R01 · FY2020 · MH · contact PI
Reservoir activity and recrudescent virus composition in HIV and SIV rebound$298,863
P01 · FY2020 · AI · contact PI
The International Workshop on HIV Persistence During Therapy$7,171
R13 · FY2020 · AI · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$383,750
R01 · FY2019 · MH · contact PI
Reservoir activity and recrudescent virus composition in HIV and SIV rebound$301,092
P01 · FY2019 · AI · contact PI
The International Workshop on HIV Persistence During Therapy$76,921
R13 · FY2019 · AI · contact PI
Revealing HIV-1 persistence in myeloid cell reservoirs$383,750
R01 · FY2018 · MH · contact PI
Reservoir activity and recrudescent virus composition in HIV and SIV rebound$326,171
P01 · FY2018 · AI · contact PI
The International Workshop on HIV Persistence During Therapy$7,171
R13 · FY2018 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,168,508
P01 · FY2017 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Core A$802,895
P01 · FY2017 · MH · contact PI
Reservoir activity and recrudescent virus composition in HIV and SIV rebound$341,945
P01 · FY2017 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Project 2$288,913
P01 · FY2017 · MH · contact PI
HIV-a Persistence in Myeloid Cell Reservoirs$230,250
R21 · FY2017 · AI · contact PI
The International Workshop on HIV Persistence During Therapy$76,921
R13 · FY2017 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,181,526
P01 · FY2016 · MH · contact PI
Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings$300,000
R41 · FY2016 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Project 2$294,561
P01 · FY2016 · MH · contact PI
HIV-a Persistence in Myeloid Cell Reservoirs$191,875
R21 · FY2016 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Core A$49,046
P01 · FY2016 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,194,404
P01 · FY2015 · MH · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$486,167
R33 · FY2015 · AI · contact PI
Molecular mechanisms of HIV persistence in macrophages and identification$463,063
U19 · FY2015 · AI · contact PI
The role of myeloid cells in viral replication, persistence and neuroinvasion$358,246
R01 · FY2015 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Project 2$300,094
P01 · FY2015 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Core A$49,046
P01 · FY2015 · MH · contact PI
The International Workshop on HIV Persistence During Therapy$20,000
R13 · FY2015 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,237,491
P01 · FY2014 · MH · contact PI
Molecular mechanisms of HIV persistence in macrophages and identification$429,638
U19 · FY2014 · AI · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$413,403
R33 · FY2014 · AI · contact PI
The role of myeloid cells in viral replication, persistence and neuroinvasion$366,763
R01 · FY2014 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Project 2$305,521
P01 · FY2014 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Core A$49,047
P01 · FY2014 · MH · contact PI
The International Workshop on HIV Persistence During Therapy$1
R13 · FY2014 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,262,306
P01 · FY2013 · MH · contact PI
Molecular mechanisms of HIV persistence in macrophages and identification$584,169
U19 · FY2013 · AI · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$425,852
R33 · FY2013 · AI · contact PI
The role of myeloid cells in viral replication, persistence and neuroinvasion$348,180
R01 · FY2013 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists$310,839
P01 · FY2013 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists - Core A$49,046
P01 · FY2013 · MH · contact PI
The International Workshop on HIV Persistence During Therapy$20,000
R13 · FY2013 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,089,177
U19 · FY2012 · MH · contact PI
Molecular mechanisms of HIV persistence in macrophages and identification$707,658
U19 · FY2012 · AI · contact PI
The role of myeloid cells in viral replication, persistence and neuroinvasion$391,360
R01 · FY2012 · MH · contact PI
Virological Measurements of Cryptic Replication$368,541
P01 · FY2012 · AI · contact PI
VIF Anatagonists: Antiviral Evaluation in Vitro, Inhibitor resistance and Mole$268,008
U19 · FY2012 · MH · contact PI
ADM CORE$63,922
U19 · FY2012 · MH · contact PI
The International Workshop on HIV Persistence During Therapy$1
R13 · FY2012 · AI · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,222,320
U19 · FY2011 · MH · contact PI
Virological Measurements of Cryptic Replication$502,507
P01 · FY2011 · AI · contact PI
Molecular mechanisms of HIV persistence in macrophages and identification$441,665
U19 · FY2011 · AI · contact PI
The role of myeloid cells in viral replication, persistence and neuroinvasion$384,123
R01 · FY2011 · MH · contact PI
Developmental Core$369,822
P30 · FY2011 · AI · contact PI
Cellular Co-Factors of HIV-1 Infection$330,988
R01 · FY2011 · AI · contact PI
VIF Anatagonists: Antiviral Evaluation in Vitro, Inhibitor resistance and Mole$289,637
U19 · FY2011 · MH · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$255,729
R21 · FY2011 · AI · contact PI
DEVELOPMENT OF ANTI-VIF COMPOUNDS$68,415
P51 · FY2011 · RR · contact PI
ADM CORE$56,306
U19 · FY2011 · MH · contact PI
The International Workshop on HIV Persistence During Therapy$20,000
R13 · FY2011 · AI · contact PI
Virological Measurements of Cryptic Replication$930,924
P01 · FY2010 · AI · contact PI
Developmental Core$373,480
P30 · FY2010 · AI · contact PI
Cellular Co-Factors of HIV-1 Infection$355,092
R01 · FY2010 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$211,155
R01 · FY2010 · MH · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$210,914
R21 · FY2010 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$105,373
R01 · FY2010 · MH · contact PI
Exploring the Role of Vif Antagonists in Preventing Sexual HIV Transmission$65,788
R21 · FY2010 · AI · contact PI
DEVELOPMENT OF ANTI-VIF COMPOUNDS$65,759
P51 · FY2010 · RR · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,331,690
U19 · FY2009 · MH · contact PI
UMASS Center for AIDS Research (CFAR)$1,297,655
P30 · FY2009 · AI · contact PI
Virological Measurements of Cryptic Replication$1,024,059
P01 · FY2009 · AI · contact PI
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$377,879
R37 · FY2009 · AI · contact PI
Developmental Core$366,163
P30 · FY2009 · AI · contact PI
Cellular Co-Factors of HIV-1 Infection$358,678
R01 · FY2009 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$337,270
R01 · FY2009 · MH · contact PI
VIF Anatagonists: Antiviral Evaluation in Vitro, Inhibitor resistance and Mole$331,054
U19 · FY2009 · MH · contact PI
ADM CORE$62,222
U19 · FY2009 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,326,345
U19 · FY2008 · MH · contact PI
UMASS Center for AIDS Research (CFAR)$1,259,859
P30 · FY2008 · AI · contact PI
Virological Measurements of Cryptic Replication$522,136
P01 · FY2008 · AI · contact PI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$462,084
R01 · FY2008 · RR · contact PI
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$377,879
R37 · FY2008 · AI · contact PI
Cellular Co-Factors of HIV-1 Infection$358,678
R01 · FY2008 · AI · contact PI
Developmental Core$355,488
P30 · FY2008 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$337,270
R01 · FY2008 · MH · contact PI
VIF Anatagonists: Antiviral Evaluation in Vitro, Inhibitor resistance and Mole$214,978
U19 · FY2008 · MH · contact PI
ADM CORE$61,114
U19 · FY2008 · MH · contact PI
Preclinical Development of HIV-1 Vif Antagonists$1,344,436
U19 · FY2007 · MH · contact PI
UMASS Center for AIDS Research (CFAR)$1,281,043
P30 · FY2007 · AI · contact PI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$460,695
R01 · FY2007 · RR · contact PI
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$385,198
R37 · FY2007 · AI · contact PI
Cellular Co-Factors of HIV-1 Infection$365,625
R01 · FY2007 · AI · contact PI
Developmental Core$345,781
P30 · FY2007 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$337,270
R01 · FY2007 · MH · contact PI
VIF Anatagonists: Antiviral Evaluation in Vitro, Inhibitor resistance and Mole$269,290
U19 · FY2007 · MH · contact PI
Administrative core$72,742
U19 · FY2007 · MH · contact PI
UMASS CENTER FOR AIDS RESEARCH (CFAR)$914,347
P30 · FY2006 · AI · contact PI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$476,979
R01 · FY2006 · RR · contact PI
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$396,703
R37 · FY2006 · AI · contact PI
Activation of CD40 by HIV and Role in AIDS Dementia$347,344
R01 · FY2006 · MH · contact PI
UMASS CENTER FOR AIDS RESEARCH (CFAR)$1,106,610
P30 · FY2005 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$372,630
R01 · FY2005 · RR
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$344,250
R37 · FY2005 · AI
Activation of CD40 by HIV and Role in AIDS Dementia$318,000
R01 · FY2005 · MH
ANALYSIS OF COVERT VIRAL REPLICATION DURING HAART$318,000
R01 · FY2005 · AI
ROLE OF HIV-1 GAG MA IN VIRAL ENTRY$312,000
R01 · FY2005 · AI
UMASS CENTER FOR AIDS RESEARCH (CFAR)$697,340
P30 · FY2004 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$361,036
R01 · FY2004 · RR
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$351,000
R37 · FY2004 · AI
Activation of CD40 by HIV and Role in AIDS Dementia$318,000
R01 · FY2004 · MH
ANALYSIS OF COVERT VIRAL REPLICATION DURING HAART$318,000
R01 · FY2004 · AI
ROLE OF HIV-1 GAG MA IN VIRAL ENTRY$312,000
R01 · FY2004 · AI
UMASS CENTER FOR AIDS RESEARCH (CFAR)$678,632
P30 · FY2003 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$439,417
R01 · FY2003 · RR
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$351,000
R37 · FY2003 · AI
Activation of CD40 by HIV and Role in AIDS Dementia$318,000
R01 · FY2003 · MH
ANALYSIS OF COVERT VIRAL REPLICATION DURING HAART$318,000
R01 · FY2003 · AI
ROLE OF HIV-1 GAG MA IN VIRAL ENTRY$312,000
R01 · FY2003 · AI
UMASS CENTER FOR AIDS RESEARCH (CFAR)$643,778
P30 · FY2002 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$427,379
R01 · FY2002 · RR
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$351,000
R37 · FY2002 · AI
Activation of CD40 by HIV and Role in AIDS Dementia$318,000
R01 · FY2002 · MH
ROLE OF HIV-1 GAG MA IN VIRAL ENTRY$312,000
R01 · FY2002 · AI
ANALYSIS OF COVERT VIRAL REPLICATION DURING HAART$276,792
R01 · FY2002 · AI
Biology and Pathogenesis of Primate Lentiviruses$5,000
R13 · FY2002 · AI
UMASS MEDICAL CENTER FOR AIDS RESEARCH$906,148
P30 · FY2001 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$415,688
R01 · FY2001 · RR
Activation of CD40 by HIV and Role in AIDS Dementia$314,334
R01 · FY2001 · MH
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$312,000
R37 · FY2001 · AI
ROLE OF HIV-1 GAG MA IN VIRAL ENTRY$312,000
R01 · FY2001 · AI
ANALYSIS OF COVERT VIRAL REPLICATION DURING HAART$274,021
R01 · FY2001 · AI
PHOSPHORYLATION AND TRANSPORT OF VIRAL NUCLEOPROTEINS$40,320
R03 · FY2001 · TW
CORE--DEVELOPMENTAL$0
P30 · FY2001 · AI
UMASS MEDICAL CENTER FOR AIDS RESEARCH$879,758
P30 · FY2000 · AI
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$404,344
R01 · FY2000 · RR
FUNCTION FOR VPR AND VPX OF PRIMATE LENTIVIRUSES$312,000
R37 · FY2000 · AI
HIV ACTIVATION BY ANTIGENS OF S PNEUMONIAE$268,750
R01 · FY2000 · HL
CORE--DEVELOPMENTAL$116,830
P30 · FY2000 · AI
PHOSPHORYLATION AND TRANSPORT OF VIRAL NUCLEOPROTEINS$40,320
R03 · FY2000 · TW
ROLE OF MONOCYTOTROPISM IN HIV/SIV PATHOGENICITY$2,163
R01 · FY2000 · RR